Comparison of Efficacy of Less Invasive Surfactant Treatment Under Nasal CPAP and Nasal IPPV
Respiratory Distress Syndrome
About this trial
This is an interventional treatment trial for Respiratory Distress Syndrome focused on measuring NCPAP, NIPPV, LISA
Eligibility Criteria
Inclusion Criteria:
- Gestational age 24 -29 week
- Clinical and radiological diagnosis of RDS
- Born in a hospital with a study center
- Spontaneous breathing
- Within the first 6 hours
- Non-invasive ventilation and FiO2 requirement >0.30
- Parental concent
Exclusion Criteria:
- Major congenital malformations
- Need of mechanical ventiation
- Need of entubation in delivery room
- Air weak syndrome
- No parental concent
Sites / Locations
- Hilal OzkanRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
NCPAP
NIPPV
Ventilator-derived NCPAP will be administered using binasal prongs. Standard Devices or infant flow-driver device. Initial NCPAP settings are: PEEP:6 cmH2O and FiO2: adjusted to keep preductal sPO2 between %90-94. Failure is defined as FiO2 requirement of >%50, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>60 cmH2O.
Ventilator-derived NIPPV will be administered using binasal prongs. Standard Devices or infant flow-driver device. Initial NIPPV settings are: PEEP:6 cmH2O, PIP: 15 cmH2O, Rate: 30-40/ bpm and FiO2: adjusted to keep preductal sPO2 between %90-94. Failure is defined as FiO2 requirement of >%50, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>60 cmH2O.